MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/09546634.2024.2421429

Медицинская библиотека · The Journal of dermatological treatment · 2024

Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network.

Zirpel Henner, Ludwig Ralf J, Olbrich Henning, Kridin Khalaf, Ständer Sascha, Thaçi Diamant

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Safety of dupilumab in atopic dermatitis (AD) was investigated in randomized controlled trials (RCT). However, head-to-head trials comparing with conventional systemic drugs are lacking and large real-world data on the long-term safety profile as compared are scarce.

OBJECTIVE

To compare long-term safety profile of dupilumab with conventional systemic drugs used in the management of moderate to severe AD.

METHODS

Data from electronic health records of AD patients treated with either dupilumab, azathioprine, Cyclosporine A, mycophenolate mofetil, methotrexate, or oral glucocorticoids were retrieved from the TriNetX US Collaborative Network. Risks of adverse events and new onset of type-2-inflammatory diseases within 5 years after treatment initiation was investigated.

RESULTS

5 propensity-matched cohorts, up to 18,708 individuals per cohort, were created. Dupilumab treatment displayed reduced risk for diseases of the circulatory, the upper respiratory, and the musculoskeletal system, infections, and type 2 diseases as compared to all other treatment options. In contrast risk for conjunctivitis was increased in dupilumab treated patients as compared to mycophenolate mofetil and methotrexate.

CONCLUSION

Here presented data indicates that treatment with dupilumab for AD has reduced risk for adverse effects of conventional systemic drugs and thus might be safer. Obtained data should be verified in prospective studies.

Для цитирования: Zirpel Henner, Ludwig Ralf J, Olbrich Henning, Kridin Khalaf, Ständer Sascha, Thaçi Diamant. Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network.. The Journal of dermatological treatment. 2024. DOI: 10.1080/09546634.2024.2421429.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.